PMID- 34012471
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210522
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - Mogroside V Alleviates Lipopolysaccharide-Induced Neuroinflammation via 
      Inhibition of TLR4-MyD88 and Activation of AKT/AMPK-Nrf2 Signaling Pathway.
PG  - 5521519
LID - 10.1155/2021/5521519 [doi]
LID - 5521519
AB  - As innate immune effector cells in the central nervous system (CNS), microglia 
      not only are essential for the normal development of nervous system but also act 
      on different neurological diseases, including Alzheimer's disease (AD), 
      Huntington's disease (HD), and other neuroinflammatory diseases. Mogroside V 
      (Mog), a natural plant active ingredient and isolated form of Momordica 
      grosvenori, has been shown to possess anti-inflammatory action, but few studies 
      were carried out to investigate the effects of Mog on neuroinflammation. This 
      study aimed to investigate the role of Mog in lipopolysaccharide- (LPS-) induced 
      neuroinflammation and neuronal damage, revealing the underlying mechanisms. Our 
      data indicated that Mog significantly inhibited the LPS-induced production of 
      proinflammatory factors, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta 
      (IL-1beta), IL-18, IL-6, cyclooxygenase-2 (COX-2), inducible nitric oxide synthase 
      (iNOS), and high mobility group box 1 (HMGB1) in BV-2 cells. We found that Mog 
      also suppressed toll-like receptor 4 (TLR4), myeloid differentiation factor 88 
      (MyD88), the phosphorylation of mitogen-activated protein kinases (MAPKs), 
      adenosine 5'-monophosphate- (AMP-) activated protein kinase (AMPK), nuclear 
      factor kappa-B (NF-kappaB), and protein kinase B (AKT). Moreover, Mog also enhanced 
      the expression of gamma-glutamyl cysteine synthetase catalytic subunit (GCLC), 
      modifier subunit (GCLM), heme oxygenase-1 (HO-1), and quinine oxidoreductase 1 
      (NQO1) proteins, mostly depending on the nuclear translation of nuclear factor 
      erythroid-2 related factor 2 (Nrf2). In contrast, pretreatment with inhibitors of 
      AKT can suppress the phosphorylation of AMPK, Nrf2, and its downstream proteins 
      expression. In summary, Mog might play a protective role against LPS-induced 
      neurotoxicity by inhibiting the TLR4-MyD88 and activation of AMPK/AKT-Nrf2 
      signaling pathway.
CI  - Copyright (c) 2021 Yuanyuan Liu et al.
FAU - Liu, Yuanyuan
AU  - Liu Y
AD  - College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural 
      University, Daqing 163319, Heilongjiang Bayi, China.
FAU - Zhang, Boxi
AU  - Zhang B
AD  - College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural 
      University, Daqing 163319, Heilongjiang Bayi, China.
FAU - Liu, Jiahe
AU  - Liu J
AD  - College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural 
      University, Daqing 163319, Heilongjiang Bayi, China.
FAU - Qiao, Chunyu
AU  - Qiao C
AD  - College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural 
      University, Daqing 163319, Heilongjiang Bayi, China.
FAU - Xue, Nianyu
AU  - Xue N
AD  - College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural 
      University, Daqing 163319, Heilongjiang Bayi, China.
FAU - Lv, Hongming
AU  - Lv H
AUID- ORCID: 0000-0002-5252-352X
AD  - College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural 
      University, Daqing 163319, Heilongjiang Bayi, China.
FAU - Li, Shize
AU  - Li S
AUID- ORCID: 0000-0002-6868-7350
AD  - College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural 
      University, Daqing 163319, Heilongjiang Bayi, China.
LA  - eng
PT  - Journal Article
DEP - 20210430
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC8105091
COIS- The authors report no conflicts of interest.
EDAT- 2021/05/21 06:00
MHDA- 2021/05/21 06:01
PMCR- 2021/04/30
CRDT- 2021/05/20 06:41
PHST- 2021/01/26 00:00 [received]
PHST- 2021/03/19 00:00 [revised]
PHST- 2021/03/30 00:00 [accepted]
PHST- 2021/05/20 06:41 [entrez]
PHST- 2021/05/21 06:00 [pubmed]
PHST- 2021/05/21 06:01 [medline]
PHST- 2021/04/30 00:00 [pmc-release]
AID - 10.1155/2021/5521519 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Apr 30;2021:5521519. doi: 
      10.1155/2021/5521519. eCollection 2021.